Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido? / Levodopa for Parkinson's disease: What have we learned?
Rev. méd. Chile
; 134(7): 893-901, jul. 2006. ilus, tab
Article
en Es
| LILACS
| ID: lil-434592
Biblioteca responsable:
BR1.1
ABSTRACT
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Dopamine deficit is the cornerstone of its clinical manifestations. Levodopa, the main treatment for this condition, was first used for PD more than 40 years ago and today it still is the most powerful treatment for this disease. In recent years many advances have been made for understanding of the neurochemical mechanisms of this drug. Furthermore, new insights about the genesis of motor complications secondary to its use are known, specially related with the mode of its administration. This article updates the pharmacology of levodopa and its implications for the pathophysiology and treatment of PD. The new available presentations of levodopa are also reviewed. The implications of these advances for the treatment of this disease are commented.
Texto completo:
1
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Enfermedad de Parkinson
/
Dopaminérgicos
/
Levodopa
/
Antiparkinsonianos
Tipo de estudio:
Etiology_studies
Límite:
Humans
País/Región como asunto:
America do sul
/
Chile
Idioma:
Es
Revista:
Rev. méd. Chile
Asunto de la revista:
MEDICINA
Año:
2006
Tipo del documento:
Article
País de afiliación:
Chile
Pais de publicación:
Chile